*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*                                                                     *x*
*x*            Copyright (C) 1990 University of Pennsylvania            *x*
*x*                                                                     *x*
*x*    The data in this file are part of a preliminary version of the   *x*
*x*    Penn Treebank Corpus.  Any research using this corpus or based   *x*
*x*    on it should acknowledge that fact, as well as the preliminary   *x*
*x*    nature of the corpus.                                            *x*
*x*                                                                     *x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*



======================================

[ European/NNP Community/NNP Commission/NNP ministers/NNS ]
are/VBP set/VBN to/TO discuss/VB 
[ proposals/NNS ]

[ that/WDT ]
would/MD give/VB 
[ pharmaceutical/JJ makers/NNS ]

[ the/DT option/NN ]
to/TO add/VB 
[ 10/CD years/NNS ]
to/TO 
[ the/DT 20-year/JJ patents/NNS ]
on/IN 
[ new/JJ drugs/NNS ]
./. 

======================================

[ European/JJ drug/NN makers/NNS ]
say/VBP 
[ it/PRP ]
's/VBZ taking/VBG longer/RB and/CC costing/VBG more/JJR to/TO bring/VB 
[ new/JJ products/NNS ]
to/TO 
[ the/DT market/NN ]
,/, as/IN 
[ research/NN ]
and/CC 
[ development/NN ]
become/VBP increasingly/RB sophisticated/JJ and/CC 
[ approval/NN processes/NNS ]
lengthen/VBP ./. 

======================================

In/IN 
[ major/JJ EC/NNP nations/NNS ]
,/, 
[ patents/NNS ]
last/JJ for/IN 
[ 20/CD years/NNS ]
./. 

But/CC because/IN 
[ patents/NNS ]
are/VBP sought/VBN early/RB on/IN with/IN 
[ discoveries/NNS ]
,/, 
[ effective/JJ protection/NN ]
is/VBZ much/RB shorter/JJR ./. 

[ It/PRP ]
takes/VBZ 
[ an/DT average/JJ 12/CD years/NNS ]
to/TO come/VB up/IN with/IN 
[ a/DT marketable/JJ drug/NN ]
following/NN 
[ a/DT patented/VBN discovery/NN ]
,/, leaving/VBG just/RB 
[ eight/CD years/NNS ]
of/IN 
[ effective/JJ protection/NN ]
under/IN 
[ the/DT patent/NN ]
./. 

[ Pharmaceutical/JJ companies/NNS ]
say/VBP 
[ this/DT ]
does/VBZ n't/RB make/VB 
[ it/PRP ]
financially/RB worthwile/VB to/TO research/VB 
[ new/JJ drugs/NNS ]
./. 

======================================

Adding/VBG 
[ 10/CD years/NNS ]
would/MD lengthen/VB 
[ effective/JJ protection/NN ]
to/TO about/IN 
[ 18/CD years/NNS ]
,/, in/IN 
[ line/NN ]
with/IN 
[ effective/JJ protection/NN ]
of/IN 
[ 15/CD ]
to/TO 
[ 16/CD years/NNS ]
in/IN 
[ the/DT U.S./NNP ]
and/CC 
[ Japan/NNP ]
,/, 
[ commission/NN officials/NNS ]
say/VBP ./. 

======================================

[ Longer/JJR patent/NN protection/NN ]
would/MD have/VB highly/RB 
[ sensitive/JJ political/JJ implications/NNS ]
because/IN of/IN 
[ the/DT possible/JJ effect/NN ]
on/IN 
[ surging/VBG social-security/NN costs/NNS ]
in/IN 
[ the/DT EC/NNP ]
,/, where/WRB 
[ many/JJ countries/NNS ]
offer/VBP 
[ generous/JJ healthcare/NN reimbursements/NNS ]
./. 

[ Other/JJ pharmaceutical/JJ makers/NNS ]
would/MD have/VB to/TO wait/VB longer/RB before/IN selling/VBG 
[ cheaper/JJR ]
,/, 
[ generic/JJ versions/NNS ]
of/IN 
[ the/DT drugs/NNS ]
,/, causing/VBG 
[ consumer/NN groups/NNS ]
to/TO object/VB ./. 
